Clinical trials: Neoplasms, Solid Tumor
Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- NCT06120283
- Testing
- BGB-43395, Fulvestrant, Letrozole
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 433 people
- Sponsor
- BeOne Medicines
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Unspecified Adult Solid Tumor, Protocol Specific
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of BMS-214662 plus trastuzumab in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00022529
- Testing
- BMS-214662, trastuzumab, pharmacological study
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04111445
- Testing
- ADG116
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Adagene Inc
Histopathologically or Cytologically Confirmed Solid Tumor Who Require Palliation Radiation Therapy to a Lesion ≥5cm
Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
The goal of this randomized, phase III trial is to to determine if Spatially Fractionated Lattice Radiotherapy (SFRT) known as LATTICE therapy, leads to a greater reduction in pain or discomfort compared with conventional…
- Trial name
- LATTICE-PAL (NCT07444775)
- Testing
- Conventional Radiation Therapy, Spatially fractionated radiation therapy
- Where
- Canada
- Volunteers
- 148 people
- Sponsor
- University Health Network, Toronto
Locally Advanced Unresectable or Metastatic Solid Tumors
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors.
- Trial name
- NCT05458219
- Testing
- IBI343, FOLFIRINOX/mFOLFIRINOX, mFOLFOX
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 470 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Tumors
A Phase I Study of G3139 Subcutaneous in Solid Tumors
Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or…
- Trial name
- NCT00543231
- Testing
- G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Genta Incorporated
Locally Advanced or Metastatic Solid Tumors
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Patients will be enrolled in two stages: Dose-escalation stage: Approximately 15-30 patients will be enrolled. Dose-expansion stage: 6-12 patients will be enrolled.
- Trial name
- NCT03478995
- Testing
- GX-I7
- Where
- 3 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Genexine, Inc.
Tumors
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of an investigational drug called DMXAA (5-6-dimethylxanthenone-4-acetic acid) or ASA404 when given together with carboplatin, paclitaxel and cetuximab to treat…
- Trial name
- NCT01031212
- Testing
- ASA404, Cetuximab, Carboplatin
- Where
- United States
- Sponsor
- University of California, San Francisco
Solid Tumor, Adult
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to…
- Trial name
- NCT05601219
- Testing
- ADA-011, PD(L)-1 inhibitor
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Adanate, Inc
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
BMS-184476 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-184476 in treating patients who have advanced solid…
- Trial name
- NCT00003705
- Testing
- BMS-184476
- Where
- 2 sites in United States
- Sponsor
- San Antonio Cancer Institute
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
NSCLC, Advanced Solid Tumor
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
This is an open-label, dose-escalation and cohort expansion study to evaluate the safety and preliminary efficacy of YSCH-01 in subjects with pulmonary metastasis of advanced solid tumors and advanced non-small cell lung cancer…
- Trial name
- NCT07793500
- Testing
- YSCH-01
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumors
A Study of ZG005 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
- Trial name
- NCT06233292
- Testing
- ZG005 Powder for Injection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Solid Tumor
A Study: Pure CBD as Single-agent for Solid Tumor.
Increasing lines of evidence support an antitumourigenic effect of cannabinoids, including the cannabidiol (CBD) which does not posses the psychotropic effects of D9-tetrahydrocannabinol (THC).
- Trial name
- NCT02255292
- Testing
- cannabidiol (CBD)
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Colon Cancer, Metastatic Colon Cancer
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors…
- Trial name
- NCT05848739
- Testing
- ST316, FOLFIRI regimen & bevacizumab, Fruquintinib
- Where
- 11 sites in United States
- Volunteers
- 130 people
- Sponsor
- Sapience Therapeutics
Advanced Solid Cancers, Breast Cancer
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
This is a phase 1 study of investigational agent CFI-402257 in patients with advanced cancer. The purpose of this study is to see how safe and tolerable CFI-402257 is in cancer patients as well as the pharmacokinetics (PK).
- Trial name
- NCT02792465
- Testing
- CFI-402257, Fulvestrant
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.